← Leaderboards
Margaret R Macdonald
Rockefeller University
$8,108,887
Attributed
$8,108,887
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $921K · FY2005–21$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$8,108,887 · 11
By mechanism
R01$5,342,922 · 3
R21$1,860,978 · 4
R03$524,737 · 3
R56$380,250 · 1
Top collaborators
No co-investigators on record.
Most similar at Rockefeller University
Same institution · by research overlap
- Charles M. Rice$80,497,748
- Hachung Chung$2,317,278
- Brett D. Lindenbach$10,442,003
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusProteinsFamilyEncephalitisPathogenMemberCellsTogaviridaeCessation Of LifeGenesAlphavirusSindbis VirusFutureInfectionIntegration Host FactorsAntiviral AgentsExanthemaVirus ReplicationFeverArthritisComplexCategoriesAffectLead
Grant awards (30)
Powassan virus nanobodies from camelid monomeric variable antibody domains elicited by natural infection$211,875
R21 · FY2021 · AI · contact PI
Powassan virus nanobodies from camelid monomeric variable antibody domains elicited by natural infection$254,250
R21 · FY2020 · AI · contact PI
Discovery and characterization of human neutralizing antibodies against Powassan virus in patients with Lyme disease for therapy, vaccine, clinical comorbidity profiling, and diagnostic purposes.$211,428
R21 · FY2020 · AI · contact PI
Elucidation of host factors required for Powassan virus replication as potential therapeutic targets$84,750
R03 · FY2020 · AI · contact PI
ZAP isoforms in innate immunity-the long, the short and the extra-long of it all$423,750
R01 · FY2019 · AI · contact PI
Discovery and characterization of human neutralizing antibodies against Powassan virus in patients with Lyme disease for therapy, vaccine, clinical comorbidity profiling, and diagnostic purposes.$267,999
R21 · FY2019 · AI · contact PI
Elucidation of host factors required for Powassan virus replication as potential therapeutic targets$84,750
R03 · FY2019 · AI · contact PI
ZAP isoforms in innate immunity-the long, the short and the extra-long of it all$423,750
R01 · FY2018 · AI · contact PI
ZAP isoforms in innate immunity-the long, the short and the extra-long of it all$423,750
R01 · FY2017 · AI · contact PI
ZAP isoforms in innate immunity-the long, the short and the extra-long of it all$423,750
R01 · FY2016 · AI · contact PI
ZAP isoforms in innate immunity-the long, the short and the extra-long of it all$211,875
R01 · FY2015 · AI · contact PI
Upregulation of ZAP expression as a novel approach for anti-alphavirus therapy$199,163
R21 · FY2013 · AI · contact PI
Genome wide siRNA screen for identifying host factors required for ZAP function$103,556
R03 · FY2013 · AI · contact PI
Upregulation of ZAP expression as a novel approach for anti-alphavirus therapy$254,250
R21 · FY2012 · AI · contact PI
Genome wide siRNA screen for identifying host factors required for ZAP function$84,750
R03 · FY2012 · AI · contact PI
Host factor DNAJC14 as a novel target for broad spectrum anti-flavivirus activity$380,250
R56 · FY2010 · AI · contact PI
Development of a genetically tractable nematode model of alphavirus infection$209,138
R21 · FY2010 · AI · contact PI
Studies on ZAP, a broad-spectrum alphavirus inhibitor$353,697
R01 · FY2009 · AI · contact PI
Host factors in the alphavirus replication complex$314,396
R01 · FY2009 · AI · contact PI
Development of a genetically tractable nematode model of alphavirus infection$252,875
R21 · FY2009 · AI · contact PI
Studies on ZAP, a broad-spectrum alphavirus inhibitor$353,697
R01 · FY2008 · AI · contact PI
Host factors in the alphavirus replication complex$314,396
R01 · FY2008 · AI · contact PI
Studies on ZAP, a broad-spectrum alphavirus inhibitor$360,546
R01 · FY2007 · AI · contact PI
Host factors in the alphavirus replication complex$320,485
R01 · FY2007 · AI · contact PI
Studies on ZAP, a broad-spectrum alphavirus inhibitor$371,315
R01 · FY2006 · AI · contact PI
Host factors in the alphavirus replication complex$330,057
R01 · FY2006 · AI · contact PI
Identification of new targets for alphavirus inhibition$82,514
R03 · FY2006 · AI · contact PI
Studies on ZAP, a broad-spectrum alphavirus inhibitor$379,875
R01 · FY2005 · AI
Host factors in the alphavirus replication complex$337,583
R01 · FY2005 · AI
Identification of new targets for alphavirus inhibition$84,417
R03 · FY2005 · AI